 SEOUL, South KoreaBUSINESS WIREGenexine KOSDAQ: 095700, a publicly traded, clinical-staged Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, today announced updated results following the completion of its Phase 2 clinical study using GX-188E, its first-in-class proprietary DNA vaccine, in combination with KEYTRUDA pembrolizumab, MSDs ...... 